-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 DrdexcSiG6VhGf7v3gN9TXdOp9uL0rEaMnnpTA/MmRPVH+UGEyI0heX83H/3Q7DR
 r8vQonCI5hrMiPphkHF1Xg==

<SEC-DOCUMENT>0001178913-08-000389.txt : 20080212
<SEC-HEADER>0001178913-08-000389.hdr.sgml : 20080212
<ACCEPTANCE-DATETIME>20080212070238
ACCESSION NUMBER:		0001178913-08-000389
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20080212
FILED AS OF DATE:		20080212
DATE AS OF CHANGE:		20080212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		08595686

	BUSINESS ADDRESS:	
		STREET 1:		72 PINCHAS ROSEN ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			69512
		BUSINESS PHONE:		011-972-3-765-8585

	MAIL ADDRESS:	
		STREET 1:		72 PINCHAS ROSEN ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			69512
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk84843.htm
<TEXT>
<HTML>
<HEAD>
     <!-- Created by EDGAR Ease Plus (EDGAR Ease+) -->
     <!-- Project:        \\backup\office\EDGAR Filing\Compugen Ltd\84843\a84843.eep       -->
     <!-- Control Number: 84843                                                            -->
     <!-- Rev Number:     1                                                                -->
     <!-- Client Name:    Compugen Ltd                                                     -->
     <!-- Project Name:   6-K                                                              -->
     <!-- Firm Name:      Zadok-Keinan Ltd                                                 -->
     <TITLE>6-K</TITLE>
</HEAD>
<BODY>

<!-- MARKER FORMAT-SHEET="Scotch Rule Top-TNR2" FSL="Workstation" -->
<HR ALIGN=LEFT WIDTH=100% SIZE=4 NOSHADE STYLE="margin-top: -5px">
<HR ALIGN=LEFT WIDTH=100% SIZE=1 NOSHADE STYLE="margin-top: -10px">

<!-- MARKER FORMAT-SHEET="Head Major Center Bold-TNR" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=4>FORM 6-K <BR>SECURITIES AND
EXCHANGE COMMISSION </FONT></H1>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1-TNR" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Washington, D.C. 20549 </FONT></H1>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1-TNR" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Report of Foreign
Private Issuer </FONT></H1>

<!-- MARKER FORMAT-SHEET="Clear All Tags-TNR" FSL="Workstation" -->
<P align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant to rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 <BR>for the month of February 2008</FONT></P>

<!-- MARKER FORMAT-SHEET="Head Center Underline-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="5"><U><B>Compugen Ltd.</B></U> </FONT> <BR><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(Translation of
registrant&#146;s name in English) </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Center Underline-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><U>72 Pinchas Rosen
Street, Tel-Aviv 69512, Israel</U></FONT><BR><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(Address
of principal executive offices) </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Indicate by check mark whether the
registrant files or will file annual reports under cover Form 20-F or Form 40-F. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Form 20-F  <FONT size="3" face="Wingdings">x
</font> Form 40-F <FONT size="3" face="Wingdings">o
</font> </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On February 12, 2008 Compugen Ltd.
(the &#147;Registrant&#148;) issued a Press Release, filed as Exhibit 1 to this Report on
Form 6-K, which is hereby incorporated by reference herein. </FONT></P>


<!-- MARKER FORMAT-SHEET="Head Major Center Bold-TNR" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><U>SIGNATURE</U> </FONT> </H1>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized. </FONT></P>


<!-- MARKER FORMAT-SHEET="Signature (Single)" FSL="Workstation" -->
<TABLE WIDTH=100% CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=40%><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=10%><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=50%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Compugen Ltd.<BR>(Registrant)<BR>
<BR>By:    /s/ Ronit Lerner<BR>&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;<BR>
Ronit Lerner<BR>Chief Financial Officer<BR>Date: February 12, 2008</FONT></TD>
</TR>
</TABLE>
<BR>


<p align=center>
<font size=2></font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px">
<HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">


</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exhibit_1.htm
<TEXT>
<HTML>
<HEAD>
     <!-- Created by EDGAR Ease Plus (EDGAR Ease+) -->
     <!-- Project:        \\backup\office\EDGAR Filing\Compugen Ltd\84843\a84843.eep       -->
     <!-- Control Number: 84843                                                            -->
     <!-- Rev Number:     1                                                                -->
     <!-- Client Name:    Compugen Ltd                                                     -->
     <!-- Project Name:   6-K                                                              -->
     <!-- Firm Name:      Zadok-Keinan Ltd                                                 -->
     <TITLE>6-K</TITLE>
</HEAD>
<BODY>

<!-- MARKER FORMAT-SHEET="Scotch Rule Top-TNR2" FSL="Workstation" -->
<HR ALIGN=LEFT WIDTH=100% SIZE=4 NOSHADE STYLE="margin-top: -5px">
<HR ALIGN=LEFT WIDTH=100% SIZE=1 NOSHADE STYLE="margin-top: -10px">


<!-- MARKER FORMAT-SHEET="Head Major Left Bold-TNR" FSL="Workstation" -->
<H1 ALIGN=right><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><U>Exhibit 1</U> </FONT> </H1>

<P align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<IMG SRC="compugen.jpg"></FONT></P>



<!-- MARKER FORMAT-SHEET="Head Sub 1 Left-TNR" FSL="Workstation" -->
<P align=center><FONT FACE="Times New Roman, Times, Serif" SIZE="3"><B>Compugen
Ltd. to Review Fourth Quarter and Full Year 2007 Results<BR> on Tuesday, February 19, 2008</B> </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Minor Center Bold-TNR" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=3>Conference call to be
held at 10:00 AM EST </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>TEL AVIV, ISRAEL, February 12,
2008 &#150; Compugen Ltd. (NASDAQ: CGEN)</B> today announced that the Company plans to
host a live conference call and webcast on Tuesday, February 19, 2008 at 10:00 AM EST to
review fourth quarter and full year 2007 results. The quarterly and full year results will
be released prior to the conference call. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>During the conference call, Martin
Gerstel, Compugen&#146;s Chairman, will provide a brief review of portions of a corporate
presentation that will be posted on the Company&#146;s website on February 19 at 7:00 AM EST. It is suggested that
participants in the call have access to the presentation during the call. To access the
presentation, please go to <U>http://www.cgen.com/Content.aspx?Page=financial_reports</U>.
The portions of the presentation that will be discussed focus on the Company&#146;s
methodology followed by its research and discovery efforts and the advantages of this
approach as demonstrated through step by step examples in selected fields. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>To access the conference call, please
dial 1-888-668-9141 from the US or +972-3-918-0610 internationally. The call will also be
available via live webcast through Compugen&#146;s Website, located at
<U>www.cgen.com</U>. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>A replay of the conference call will
be available approximately two hours after the completion of the live conference call. To
access the replay, please dial 1-888-326-9310 from the US or +972-3&#150;925-5900. The
replay will be available until 12 noon EST on February 22, 2007. </FONT></P>

<p align=center>
<font size=2>1</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px">
<HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
<P STYLE="page-break-after:always"></P>


<!-- MARKER FORMAT-SHEET="Head Left-TNR" FSL="Workstation" -->
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>About Compugen <BR>Compugen&#146;s mission is to be the
world leader in the discovery and licensing of product candidates to the drug and
diagnostic industry. Our business model focuses on maximizing the number of products in
the development pipelines of pharmaceutical and diagnostic companies worldwide under
revenue sharing licensing agreements. Our means to accomplish these objectives relies on a
growing inventory of powerful proprietary discovery engines that enable the predictive
discovery &#150; field after field &#150; of numerous therapeutic and diagnostic product
candidates. This capability is built on the Company&#146;s long-term pioneering efforts in
creating world-leading computational biology platforms, systems and tools, and in
obtaining deeper understandings of important biological phenomena at the molecular level.
Included in our growing list of collaborations are Biosite, Diagnostic Products
Corporation (a Siemens company), Medarex, Inc., Merck &amp; Co., Inc., Ortho-Clinical
Diagnostics (a Johnson &amp; Johnson company), Roche, and Teva Pharmaceutical Industries.
Compugen has established an agricultural biotechnology affiliate &#150; Evogene, and a
small-molecule drug discovery affiliate &#150; Keddem Bioscience. For additional
information, please visit Compugen&#146;s corporate Website at <U>www.cgen.com</U>. </FONT></P>


<!-- MARKER FORMAT-SHEET="Para Flush Lv 1-TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><I>Company contact:
</I><BR>Naomi Rabbie
<BR>Corporate Communications Manager
<BR>Compugen Ltd.
<BR>Email: <U>naomir@cgen.com</U><BR>Tel: +972-52-598-9894 </FONT>

</TD>
</TR>
</TABLE>
<BR>


<p align=center>
<font size=2>2</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px">
<HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">



</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>compugen.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 compugen.jpg
M_]C_X``02D9)1@`!``$`E@"6``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``0"`P,#`@0#`P,$!`0$!@H&!@4%!@P)"0<*#PT/#PX-
M#@X0$A<4$!$6$0X.%!P5%A@9&AL:$!0='QT:'Q<:&AD!!`0$!@4&#`8&#!D1
M#A$9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9
M&1D9&1D9&?_$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`&L!``,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/OZ@`H`*`"@`H`0G`H`H76NZ-:W#P7&K6$,L9PT<EPBLI]P
M3Q5*$FKI`1_\))X?_P"@YIG_`(%1_P"-/V4^S`/^$D\/_P#0<TS_`,"H_P#&
MCV4^S`JZQXW\&Z19F[U7Q;H5A;@X,UU?Q1IGTRS`54,/5F[1BW\@-FQN;>\L
MXKNTFCF@G021RQME74C(((Z@BLFK.P$M`!0`4`%`!0`4`%`!0`4`%`!0`4`%
M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`$5U,(;=Y=COL4MLC7+-@=`.YI;@>5:E
M\5?%LC3VR?`OQM/;MN0/YEO&77IG'F97(_&O2C@:>C]M'\?\A'FMQX7\#SSO
M/<?L;7\TLK%WEE@LV=V/4DF3))]37I1KXB*M'%V7J_\`(FR[#/\`A$O`(_YL
MPNA_VZV7_P`73^LXG_H,_&0:=C'\9>%]$.ANG@_]C?3$U-B`DFKPVOD1CN2L
M;[F/L"OUK6CB*O-^^Q;MY-W_`!#;9'3?LQ?"`:K<7&M_$?X)?#CPZEI*GV"W
ML-'*W#NI#>:6:9U"@XP,9)R>,<\V99BX6AAZ\Y7WN]/0<;]3Z810@PHP!7SY
M0M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`8'Q
M`\;>$O`^F0:CXO\`$.GZ):7,OD137LPC5Y,%MHSU.%)_"M:.'JUI<M*+;\@/
M!/%/C#X?ZUXAN]33]KZ]TN.X<LECIUS91P6Z]E0&(G`]6))[FO;HX:O3@H_5
M;^;YO\R?F4/[<\`?]'HZ]_X'6/\`\9K3V5?_`*`U]TO\Q?,/[<\`?]'HZ[_X
M'6/_`,9I^RK_`/0&ONE_F'S/./&?Q,\$ZC'J'AZ_^,'QKUG36<PO);P6`@NT
M!ZJ3M8H?<#(]C7?1P-56J*C33\W*Z_&Q+DC`^'GA#X(^-_'&F>$=+UOXM+=:
MO-Y*M)#8QH@P2Q+*Q*C`/(!(K?$XC&8>FZLHPLO\0HI-VU/T%T6PL]*TFUTS
M3[:.VM+*);>"",86.-0%50/0``5\))N3YI;FVQ:H`*`"@`H`*`"@`H`*`"@`
MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`/2@#@?BBGQ-EUV"/PCX4\#:OI
MJ0AC+X@U&>"9)22&"HEO(-NW;SG)R>..>O#>P2;JRDGY+_@H3OT.:^R_'3_H
MFOPB_P#!S=?_`"%73S83_GY/[E_\D+W@^R_'3_HFWPB_\'-U_P#(5'-A/^?D
M_N7_`,D'O&'\2+/X]_\`"#:B]OH'PC\*M"BS-K(U69Q:1HP:1B)+$K@HK*2>
M@;/:MJ$L$JBYI3EY66O_`),+WCR#^T/C=_T7'X*_^#2#_P"0:];V6#_Y\U/N
M?_R1/O\`D=!\*O$GQ*T3XA:7JGC#XQ_""]T&WD)O8+35H1*8RI!*8LT.1UQN
M&<=:Y\70P\Z3C1HU%+I=:?FQKF3U/KFSGAN;6.XMI4EAF4/')&P974C(((Z@
MBOE[6T9H2T`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`
M%`!0`4`<Y\2_!6B>.="CTG7/MR0PS+/')8WDMK*C@$</&P.""00>#GZ5M0Q$
MZ$N:'XI/\PL>#>/O"/PJ\(>)'T;4=$^--W(B+(MQI<FJ7D$BGNLD3,/J#@CT
MKV:%?$UH\T907KRI_B0TD8OD?!K_`*%GX_?^`>MUM;%_S4_O@+0;+:_!:2)X
MI?"OQ[DCD4J\<ECK3*RD8((/!!'8TU]<6JG3^^`:'"^.O#GPPLKR`>#O@-X_
MUFV=/WOVVQU.TDB8'C&8B&!'H<BNVC5Q4D_:UXQ]'%_J)I=$8?\`8^@C_FU_
MQG_WWJ/_`,9K?FJK_F*C_P"2_P"8M/Y3U7X(?&+Q!X"L[3PW#\"O']MX<2;Y
MOW%[=R6:'KY2O$/E!YV`],X["O+QF6PK-U/;Q<O5*_XE*36ECZSL+B.ZLXKF
M$L8YD612R%3@C(R#@CZ'FOF;6=C0FH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`K:M%=2:9<16%R+:Y>-EBF9-XC<CY6*]\'
M'%-63NPN>*B7XWQ_)-\9/ADLB?*X_LUAAAUX\[CFO7_V+_GU/[_^`(//^-?_
M`$67X9?^"YO_`(]1_L7_`#ZG]_\`P`#S_C7_`-%E^&7_`(+F_P#CU'^Q?\^I
M_?\`\`#PKXMZ-K_A?Q0W_"0?M-W5C-JI>\2VTJ;4YH(P6Y"[)VV#).%)X'3B
MO9PE2E4A:EAKI=^6_P"*,Y:=3EQJ!_Z.I\0?]^]8_P#CE=7*MOJJ_P#)?\B;
MK^8^J/V%]2>_^$NI0-\09_&RZ?K$L"ZC<0SI)$&BAE\IC,2[X,I8'.`'"C[M
M?,YQ!0KZ4^2Z6FGZ&L=M#VBO**"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`,#XC:Y?^'_``XU[I?AC4?$5T9%C6PL&17(/5BS
MD``#W]*UH4XU)\LI**[L-CY]F\(^#I9GFE_8TE>21B[NZ6)+$G))._DYKWE7
MK15HXS3UD3\AO_"&^"_^C,&_[]V/_P`73^LU_P#H,_&0QDOA+P-"FZ;]C58E
MZ;I!8*/S+T_K%?IC/QD!POB/POXO'B"[;PI^S-\.[#1V8?9H+ZW@DG"@#)=D
MN%7).>`.!CDUV4Z]+D7ML3-R\F[?*Z);ET12_P"$7^*3$)'^SI\,7=ONHE@A
M+'T`%U5>WPJU^L3^]_Y"][L?7_P.\*+X.^&VGZ3)I&B:7?.OVB^@T2V,%K]H
M?ERBEF/H,DG./PKY7%U_;57*[:Z7U=C0ZZN8`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`Z4;`<C\0OBA\/O`MU%;>+O%^E:1-.,I%<S
M`.1Z[1R!]:Z*&#KXC^%%L+I'#>-/CO\`"+6-$>PTGXWZ7H$TA&Z^LQ'),B^B
M"5&0'IR5;^H[J>4XN$KRHM^7_#"YD>>#Q/\`#8#_`)/-\6_^!-C_`/(E=WU;
M$_\`0)'[I?\`R1%O,/\`A)_AM_T>;XM_\";'_P"1*/JV)_Z!(_=+_P"2#YG&
M>*/B]X7TO57M--^.7QHUN*/@W=G'IRQ,?]DO;@L/?&*ZZ.759J\J-./D^;_Y
M(3=NIQWCOQI\./&L<$7BWQK\:]8BM26BBNFTTHC'N%$0&??&:Z\/A<3A[NE"
MFG_V]^K%==V7_A#\'OAQ\2=66U\,:?\`%EK8-MFU*XCTR.V@]<N8N3[+DU&+
MS'$82/[QT[]O>O\`F-03V/J3]G_]GCP%\)]2GU?2Q>ZMK$V574M5,;201_W(
MA&B*@/<XW'N<8`^;QV;5\8E&5E%=%_P6V7&*B>MUYA04`%`!0`4`%`!0`4`%
M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`A(%`'%_$K4/BG;ZI!#X!\-^%=0M/
M+W37&M:O-;-OR?E5(X).``#DGOC'&:Z</'#M-UI->B3_`#:$[]#D9F^/LMPT
M\WPY^%$DKX#2/KET6..F2;.NI?4EHIS^Y?\`R0O>&_\`%^O^B;_";_P=W7_R
M'1?!?SS^Y?\`R0>\8/CCQI\2_!T=N?%>@_`_0C>[UMCJ/B.XB$I4#=MS:#=C
M<N<>H]:WH8>A7=J3J.V]HK_,/>/&;[Q)\5KJ\DN#^T+\(;<R,6\FUUB*.)/9
M5^RD@#W)/J2>:]F-#"Q5OJ]3YI__`"1+OW+'AMOC9X@UN#1M`^._PUU34;G)
MBM+/5HY)'P,G"BSST!J:GU*C'FJ4)I>:?_R0*_1GT%\"_AAXZTGR]5^)OCN3
M7+W!QI5I#$EG$3W9Q&KRGZ[5Y^Z<`UX.-QE&?NX:'*N[>O\`DBXIVU/6K6V@
MMH1%;PQQ(O(6-0H_(5YCUW&2CB@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@`H`1NG%)@?)_B"+X-/XAU%[SPA\;FN6O)FF:"'4S&9#(
MVXIM?;MSG&.,8QQ7TE*>*4$HSIVMUY;_`(DZ%3R/@E_T)WQT_P"_.J__`!=:
M<^+_`)Z?WP#0/(^"7_0G?'3_`+\ZK_\`%T<^+_GI_?`-#B_B78^$+C5[5?"W
MP3^(?B*RBA):;7+C589(9&;YE12&^4A4.0>2/:NO#3JI-U:T(ORY61*VUC`M
MM!@N+J&V@_9GU\RW$BQ1A]3U)%+,0HRQ0!1DCDG`K>5?E3?UE?='_,5E_*?9
MWP(^$WA+X;:0\NBZ%;V.J7\:?;I4N)+@[@.4223YM@.<#C/7%?)8S'U<4_WC
MNEMT_!&J26QC?'']H?P!\,]3.BWDMYJ^MJ`7TW2T5V@!&0978A$[<9+8.0I%
M;8+*<1BES15H]WH$I*)YC9?MKZ,UV%NOA]J:6X.&:"_BDD`]E(49^K#ZUZ4N
M&JJ6DU^)'M$?0/PH\>>'?B)X'MO%7AF[>:RG)1TF3RY;>1?OQR*?NLIZ]0>"
M"003X6(PU3#5'2J*S1HFF>4_%']K/X=^%M:GT?0[;4/%%U:DI+/8;$M$<'!3
MSG/SD>J*R]LY!%>GALAQ-:*G*T4^^_W$N:1SF@?MI^&);Y$USP3K.GVC'#7%
MI.ET4']XIA20/]G)]`:Z)\-UDO<FF^VQ*J(]N\8?$SPQH7P:G^)L=P^J:%%:
MK=Q26&TM<HQ`4)N*C))`P2*\:CA*E2NL/:TKVU+NDKGE&@?MA_#[4]=L]-D\
M/>)-/2ZE$;WEZMJD-NO\4CD3$A5&2<`GC@$UZE3A_$0@Y\R?DK_Y$JHC)U;]
MM/PO%K+1Z7X(UN]TU7P+N6:."61<_>6)LD9Z@,5/J%/36'#=9QO*:3["]HC>
M^('[6_P]T/2].FT&TU#Q!>:C;)=&UA"PBT5OX)G;(63((VJ&(QS@$$X8?(,1
M4DU)J*6GKZ>0W-+8Z;]F[X]Z!\7+R^TJWTF\T?5[",3O:7#K(DD1.W<CKUP>
M""`1D=:YLPRNI@DI-W3Z^8XR3.0\0?MA^`=*\0ZEI!\,>*KIM-O)[)I[>.V,
M<IBD:,NF9@2I*$@D#((KKH\/8BI",^9*ZOKY_(7.BGXJ_;+\&V1MDT#PMK&K
M.\*2W!EDCMT@=E#&+/S%W4DJQ`VY'#-SBZ7#M>=^>2B)U$MCT_X"?&;PS\4_
M"M_JNE0W5A<Z.0+^PNPOF0`J2K@J2&1@K;6']U@0""!YN.R^K@YJ$];[,J,D
MU='F,_[:?P^C\S;X0\7R",L`5BM?GP<<9G[UZ2X;Q#^U'[W_`)"]HCM?C'^T
M/X8^&RZ"NMZ!K]Q/KUB+](+1("UNAQ\LFZ11NR2.,C@\UQ8/*JN*YN1I<KMK
M_P`,-R2+OP!^.GAWXLW>L1:+HFM:9'HD44L\^IK"J'>7X!21N0$R<XX(J<=E
ME3!<O.T[]F.,D]CS_P`<?MD>"=-UA[3PKH.H^)+>)BIU!95MK>7WB+`LZ_[6
MT`]02.:[J'#U><5*HU&_3J2ZB6Q(_P"V7\/8]*L;@^'/$TES<*_VBUAB@)M6
M4@`%FD4,&SE2N>`<[2,4EP[B>9KF6GGO^'02J(]*^`WQ@T/XJ:!JFM:5I6J:
M39:3*(99-4$2!CLWD@H[#`&,DD5Y^-R^>#FH2:;?8M-,\Y^(7[87P_T35)K#
MPWI>I>)?L[%6O82MO:,1P=CO\SC/\07:1R&->AA^'L14CS3:CY:W^Y$NHEL0
M>`?VQO!FK:[;Z?XD\/:EX>ANI%B2^,J7$$9/`\PKAE!.!D*0,\X'-.OP]7IQ
M<H24K=-F$9INQZ3^T%\:/#GPBL](GUO3]3U$ZU)(D$6FK$S!44,SG>ZC;\RC
M@GEA7GX'+JF,<E3:5NY4I*)P>C?MA?#>\L]1NKK1O$FG)I\"RHD\,#27<C-M
M6&)4E)+GDDG"J`2S`<UVU.'\3!Q2:=_P\WH)31F^$/VR/#&J>++/2]6\(:II
M-E>W"6ZW_P!H281%V"JTB``A<D9*EL=<$9K2KP]6A3<XS3:5[>A*J*]CZ67I
M7SYH+0!Y)\21X^T[Q;<-#\:_"WARPNV,EG8:GIL1E1``&^9I5+@-GG'<"O1H
M/#N%I4G)]T_^`)W,'^T?'O\`T<EX!_\`!=;_`/QZMO\`9_\`GQ+[W_D+7N']
MH^/?^CDO`/\`X+K?_P"/4?[/_P`^)?>_\@U[G"?'FPUC4?#T.N^)?VEK)8-%
MWX7PO$T<S"5HU.Z."XS(`57'!*@L>A-=V!J4XSY*6'U?\VVGJM!-/N6_V'M+
MTO4_B5J6MV'Q<\5^+UT:S$;66HI=PPQ/,Q"N1+(RN=L;@#'&<^E3G,Y1I1A*
MBH7=[JW3T007F>^_''Q6?`WPA\2>+8U#3:1ITUQ!&>DDP4B-3]7*C\:\3!T/
M;UX4N[2*;LC\U]!TW4O%?C2RTE[R674_$6HQP2WA.9'EFD`>3GOR3^`K]$J3
MCAZ3DEI%;',E=ZGUM^T/\`_A[JVNZ1::/XQ\+>!(])L1;-8ND2R3C/RN^75F
M.`1N;)/.2:^3P&:UJ:DYQ<[NYM*%SB?B'H[_``1_9?U71?#WCJW\0#QOJZV_
MVS3\*D4:Q8F4%6;YB$`//3BNS#S688V,YPMR+9_@*W)$\O\`V5/!%EX[^.>B
M^'M1MQ)I<(>[O(1PKQ1KD(<=BQ4''K7JYKB98?#2G%ZZ)$4XZZE#]H:VT.Q^
M.OBNQ\-645EI5I?F"WMX?N(415?;[&0.?QJ\M<WA8.H[NWZZ"DM6=SXHUB[T
MO_@G_P"%O#\DA'_"1>))F2)CS]DA>28L/]GSDB'_``,>M<-*G&>:3FOLQ_%V
M7Y7*?P&#^R+X(TGQ]\<+72?$%H+K1["RGU&\MRQ42*FU5!(YQOD0X]JWS;$S
MPN'YJ;M)NR_,5-)O4\WU6YL)M0OKS3(_+T^2>:6T3.[;`78QC/?Y-M>E34N5
M*>^E_4E^1ZE^TAX*\.>!/"/P\TW3]/6'7=1TDZAJMSO8F9FVXR"<#!+`8`X%
M>7EN)J8BI5G)^ZG9%SBDE8Z?]@P+HEWX]^(,VU8O#NAL$9NF\[I/Y(!7-GKY
M_9X=;M_\`JFK:G@-M!>7IAM+7#7U](D$.[D&61@JY_X$PS7O7C!7Z+]#+<]O
M_;?\#>#?AWK/@KP[X5T^.UN_[,GEU*0.6><AH4B>3)ZDB?!&.C>V/&R3$UL1
M&I.J[JZM^-_T+J*UBA^S)J]WX8^&/Q>\3VS*/LN@PVL8+8W3RO*L8_G3S2"J
MUJ%)]9/[M`@[)L\V^&VAMKOCSP_X<B`;[??V]K@]P74'/X9KT\35]E2G4?1,
MF.YZ9^W=K::K^T;J%E`P-OH5I!8(`>`0N]A^!?'X5YN1T>3"*3ZMLJIN,T:_
MN/"'[$NI/:2-#=?$'7C8R.G!-I%'^\&?1@FP^SFE."K9BD]J<;_,<;J&AS_[
M+?@BS^(/QST;P[JD32:6GF7E[$I(\V*,9$9(Y`9BH..V1WKIS3%2PV&E.&CV
M1--)LK?M(6'A_2OCSXITGPK8QV6E6%VMM%;Q$[4=8T$F,_\`33?59;*<L+"5
M1W;%/?0['7]5OO"?[#7A?0;626VE\?:E=ZA=E3C?:I(50`C^%T2$GV)%<=.G
M&MF4ZC^PDEZV_1W+=XPL>?\`PBOKO2/%G]LVGP_;QG]BC(^Q-8374,+M]UW6
M)6]&P&X//I7?C(J=/D=3DOUNE?[R87WL0^,-#\6ZQK>I:I!\,_$6F1WTKS+8
MV>@7@A@W<[$!CX7T%.E5HTXJ+JIVZN2_S#E=[V/0OVUM4O9O&?A'PW>2L[>'
M/#-M'*C@ADN)OFE!S_L1P?K7GY+32IU*J^U+\%_PXZNZ*GPG\&>&)?V9/B3\
M1O$VG_:KC3(QIVCLSLHBN7"JC#'4F66)><]#6F+Q558RCAZ3M?5_UZ!&*Y;L
M\_\`ASH[^(/B/X;T"/KJ6JVMN3_LF5=Y_P"^0U=^*J*G0G-]$R(J[2/U+7I7
MYJ=0M`''_&'PEX<\0>'WU#5OAWHWC.^TR-GLK'4+>%F9CC*H\H(3./H<"NG#
M8BK1E:G4<$][-_H#/&AX:T[_`*,KT3\]+_PKU_;S_P"@Q_\`DQ.O87_A&M._
MZ,KT3\]+_P`*7UB?_08__)PN^PJ>&[!&#+^Q;HJD="K:6"/TH]O/_H,?_DPM
M>QT'[)6A^-]$\3>)!XF^&WA[PCI]TL+63Z3:6\$DVUY/DF,1(8JK#!Z<MCK7
M/F=2C.,/9U')K>[;^ZXXJW0])^-O@Y/'_P`*/$'@YI_LS:O9/!%.1D12]8W(
M[@.%)'?%<&$Q#PU:-9=&4UI8^!C\//C!\.?'=CJ?_""ZP=1T:[2YM[BSLVN[
M=W4\$&/.5/O@\U]O]<P>*I./.DFMF[,YU!QU1LM\*/C9\9?B'=^(=:\,7%G=
MZFZ^=J.L0?9H($`VJ%0_/M4#A0.>>><UE''X/`4E3IRNET75^H<LI.[/H3XR
M?LZK<?LSZ)X#\%21F_\`"TGVN!IP(Q?2MN\XMCA6<NQ'8'`KP,%F[CBY5Z^T
MM'Y=ON-91TLCYE\(:)\;?AGXQ;4M#\&^)M.U4PO;&1-+:Y0HW7E0R]@0<\$"
MOI:U7!8NGRSFFO6QDE*.QT'PE_9N^)?C?7DN/$>GWGAW2YI3)=WVHX%S)DY;
M9'G.XY/+8`Z^U<V*SC#X>/+2?,TK*VPU3;>IWW[;'PZ\67VL^#O"OP_\"ZK>
M^'O"VDM!";*)3'&SLHVY+#D+$F?K7%DN,I152K7FE*3Z_/\`S+G'30J?LS_#
MWXA^"OAA\4_$5SX/U>UU^^TI-,T>R:-1.[E9"73#8QNECSR/]559EC,/7KT:
M:FN5.[?3I_D*$6DSR?PK\"_BA<Z_H^DWGP^UVQL+B]MK6>YDB39;P-*B22'#
M=%0LWX5ZE?-,-&$I1J)NSMZVT(4'<](_;*\"_$OQ?^T%J.H:'X"UR]TFRM+>
MRM9X(T,;A5+,5RPXR^.G\-<&3XO#4,*HSFDVVV7.+>PL6BZ[\,/V%O%">(-(
MN])U?Q7J\=B+>Y`5UCRHR<$\%4D_.I=2&+S*'LW>,4%N6.IXA\/-!\1>(_&%
MIIGA."276$)NK58W"L&B^<%2>,\#&>M>WB:M.E3<JNW^>AE%.^AUWB'PI\<?
MB9X_>^USPEXDO]:G5(&FO+(VT,*+D!0Q`15!)/&>23R37'3Q&"PE/EIS2COH
M[LMQDV>_>*/@!K7AG]C+4_!OAY1J?B6]O8=7U%83C[7(K)F*//94C4*#U*YZ
ML:\.GFL*N81K5-(I67EY_>S3EM&R/GSX6?#?XPOX_P!/D\,>$M>TG5;*X$D>
MH7MF88K5A_$S2#:1@G@;L]*][%8W!^Q:J333Z)ZLRC%WT#Q-\)/C1=^(M3O;
M[P+XCU2[GN9'FOC$G^E-N/[SENC8!'MBG1S'!1A%1FHJVVN@W"5]3W_Q_P#`
MZ^UC]D?P;X9MYK&P\4Z#&M^MM>2+%YK2`^="2?NM\PYZ;D&?4?/T,U5/'5*L
MM82T_P`F6X^[8\>^&7P8^/-AXL2Z\-6DWARY3,,FJIJ$(2&-OO9*ELC'.,9X
MXP>:]C$9G@)T[5'S>5B(PDCQQVDO$=K&>2[ENW/D3L69KAG;Y7)/)+$AN>>>
M>:]=6@O>5DOP\B=V?:?[4WP-UO7?@AX,TWP?;+<WW@FSCM%T_<%,\(B1"$)X
MW#8#@]>:^.RS,X4L3.=9Z3=[]G>YM.-T>!_"R[^._P`,GUK3O"G@KQ%:3:W&
MD5R9-%ED9"FX*R/C:&&]N<D<^U>YBHX#%<LJLU[M^IG%2BK(]+_9N^$GQRUO
MQC8ZQX]\8^/-%T*RD6>2TN_$EX9[T@Y";!,0JYQG/;@#FO.S',,'"FX4(1<G
MUY59?@7%2W9Q/[17P]^*WBSXY>)]?M/AYXAN;2XO"EO,L28>)`$4C+="%XKN
MR[&86AAH0=1)_P"9,XML[+Q5\._'^E_L-^'/`^E>$]7NM6UC6/[1U6QAC4O`
M@=YE63YL<2+#CD_=KAHXRA+,I5I22BE9/Y6_S&XM1L9'['/PB\=Z?^T-HVM>
M*?!^J:1IVCP7%V)[R-0CR[/*1!ACS^]9A_N5OF^84)85TZ,TV[;??^@H1:>I
M]OKT%?&HV8M,`([4`)M%+E2'<,#WHL@N&![T607`#%%A"TP$P/>E8=PP*+"%
MQQBG:P"8^HI6``,4]@`CBE8`VCWHL`;1[TPV`J/<4K`>&_ML?#7QQ\3=$T'2
M?"45DT%E<R7-R;JX\O)V[4`&.>I->QDV-HX2<IU;[6T(G&ZLCD?V//@%XT^'
MWQ6N/$WB^+3T@BT]X+7[+<^8WFNRYR,=-H-=F;9M1Q-%4Z5]];BA#E/J#;]:
M^;L:+0,4P#;]:`#;]:5@/G_]M3X":C\5Y])U_P`/36/]JZ5"]LUK?#"3Q%@P
MVO@[6!SUX(/;'/N9/FBP7-3J7Y7V)G&^QX%HO[.GQ\TBPU#2='TU],L=73R;
M^"RU988;M,$;954C>N"00>H)!X)%>[/-\#-J<W=K:ZO8S49H]8_9K_98O/#G
MC"R\6_$"]M+B?2Y1/9Z5:9>,2C[LDCG[VWJ%`QD`YX%>5F.>*M3=&@K)[ME0
MIVU9]2X`KYNQH&*+`M```HL`;?<T6`,"BP`%QZT6`6GL`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`'
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
